Search

Displaying results 1411 - 1420 of 4236 in total
  1. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

  2. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    It is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.

  3. Drug

    Tazarotene

    go.drugbank.com/drugs/DB00799
    Approved

    Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. … It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).

  4. Drug

    Taurocholic acid

    go.drugbank.com/drugs/DB04348
    Approved

    It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.

  5. Drug

    Adalimumab

    go.drugbank.com/drugs/DB00051
    ApprovedInvestigational

    A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.[L45643,L45818]. … [A39983] This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system.

  6. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  7. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  8. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...

  9. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued pl...

  10. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia